Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APTX NASDAQ:FPRX NASDAQ:GLYC NASDAQ:PTGX NASDAQ:XOMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTXAptinyx$0.10$0.08$0.01▼$0.72N/A1.271.32 million shs231,126 shsFPRXFive Prime Therapeutics$38.00$37.94$2.61▼$38.90$1.77B4.41.98 million shsN/AGLYCGlycoMimetics$0.16-6.6%$13.48$14.06▼$63.00$10.00M1.6267,672 shs1.05 million shsPTGXProtagonist Therapeutics$62.14+4.9%$56.19$33.31▼$62.21$3.87B2.22939,313 shs1.36 million shsXOMAXOMA Royalty$37.59+2.3%$30.53$18.35▼$38.45$454.46M0.9945,216 shs63,866 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTXAptinyx0.00%0.00%0.00%0.00%0.00%FPRXFive Prime Therapeutics0.00%0.00%0.00%0.00%0.00%GLYCGlycoMimetics0.00%0.00%0.00%0.00%-99.06%PTGXProtagonist Therapeutics+1.08%+2.56%+5.35%+9.83%+31.86%XOMAXOMA Royalty-0.94%+0.44%+15.75%+49.23%+28.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTXAptinyx$0.10$0.08$0.01▼$0.72N/A1.271.32 million shs231,126 shsFPRXFive Prime Therapeutics$38.00$37.94$2.61▼$38.90$1.77B4.41.98 million shsN/AGLYCGlycoMimetics$0.16-6.6%$13.48$14.06▼$63.00$10.00M1.6267,672 shs1.05 million shsPTGXProtagonist Therapeutics$62.14+4.9%$56.19$33.31▼$62.21$3.87B2.22939,313 shs1.36 million shsXOMAXOMA Royalty$37.59+2.3%$30.53$18.35▼$38.45$454.46M0.9945,216 shs63,866 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTXAptinyx0.00%0.00%0.00%0.00%0.00%FPRXFive Prime Therapeutics0.00%0.00%0.00%0.00%0.00%GLYCGlycoMimetics0.00%0.00%0.00%0.00%-99.06%PTGXProtagonist Therapeutics+1.08%+2.56%+5.35%+9.83%+31.86%XOMAXOMA Royalty-0.94%+0.44%+15.75%+49.23%+28.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTXAptinyx 0.00N/AN/AN/AFPRXFive Prime Therapeutics 0.00N/AN/AN/AGLYCGlycoMimetics 3.00BuyN/AN/APTGXProtagonist Therapeutics 3.08Buy$68.089.56% UpsideXOMAXOMA Royalty 3.33Buy$69.5084.89% UpsideCurrent Analyst Ratings BreakdownLatest PTGX, APTX, FPRX, XOMA, and GLYC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/17/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.009/17/2025PTGXProtagonist TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$72.009/16/2025PTGXProtagonist TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$72.009/12/2025PTGXProtagonist TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/12/2025PTGXProtagonist TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$73.009/10/2025XOMAXOMA RoyaltyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/12/2025XOMAXOMA RoyaltyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/7/2025PTGXProtagonist TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform8/7/2025PTGXProtagonist TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$67.00 ➝ $69.00(Data available from 9/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTXAptinyx$1MN/AN/AN/A$0.57 per shareN/AFPRXFive Prime Therapeutics$14.87M119.01N/AN/A$4.13 per share9.20GLYCGlycoMimetics$10K1,000.25N/AN/A$0.08 per share1.94PTGXProtagonist Therapeutics$434.43M8.90$4.79 per share12.97$11.33 per share5.48XOMAXOMA Royalty$28.49M15.95N/AN/A$6.95 per share5.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTXAptinyx-$64.85M-$0.98N/AN/AN/AN/AN/AN/AN/AFPRXFive Prime Therapeutics-$137.20M-$3.92N/AN/AN/A-554.71%-75.84%-49.08%N/AGLYCGlycoMimetics-$37.88M-$0.46N/AN/AN/AN/A-230.74%-177.39%N/APTGXProtagonist Therapeutics$275.19M$0.7088.77N/AN/A24.88%8.12%7.41%11/6/2025 (Estimated)XOMAXOMA Royalty-$13.82M-$1.55N/AN/AN/A-27.57%2.63%0.97%11/6/2025 (Estimated)Latest PTGX, APTX, FPRX, XOMA, and GLYC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025XOMAXOMA Royalty-$0.12$0.48+$0.60$0.44$9.39 million$13.13 million8/6/2025Q2 2025PTGXProtagonist Therapeutics-$0.53-$0.55-$0.02-$0.55$8.32 million$5.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTXAptinyxN/AN/AN/AN/AN/AFPRXFive Prime TherapeuticsN/AN/AN/AN/AN/AGLYCGlycoMimeticsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/AXOMAXOMA RoyaltyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTXAptinyxN/AN/AN/AFPRXFive Prime TherapeuticsN/A5.355.35GLYCGlycoMimeticsN/A1.921.92PTGXProtagonist TherapeuticsN/A16.9716.97XOMAXOMA Royalty1.414.884.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTXAptinyxN/AFPRXFive Prime Therapeutics67.28%GLYCGlycoMimetics75.19%PTGXProtagonist Therapeutics98.63%XOMAXOMA Royalty95.92%Insider OwnershipCompanyInsider OwnershipAPTXAptinyx10.97%FPRXFive Prime Therapeutics6.40%GLYCGlycoMimetics8.70%PTGXProtagonist Therapeutics4.90%XOMAXOMA Royalty9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPTXAptinyx12N/AN/ANot OptionableFPRXFive Prime Therapeutics8746.57 millionN/AOptionableGLYCGlycoMimetics5064.53 million58.90 millionOptionablePTGXProtagonist Therapeutics12062.21 million59.16 millionOptionableXOMAXOMA Royalty1012.09 million10.99 millionOptionablePTGX, APTX, FPRX, XOMA, and GLYC HeadlinesRecent News About These CompaniesXoma announces closing of tender offer for HilleVaxSeptember 17 at 3:42 PM | msn.comHilleVax Acquired by XOMA, Delisting from NasdaqSeptember 17 at 9:50 AM | tipranks.comXOMA Royalty Corporation Completes Tender Offer for HilleVax, Inc. Shares and Merger FinalizedSeptember 17 at 9:31 AM | quiverquant.comQXOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.September 17 at 9:00 AM | globenewswire.comXOMA Royalty (NASDAQ:XOMA) Upgraded to Strong-Buy at Zacks ResearchSeptember 14, 2025 | marketbeat.comThe Pharma Letter M&A roundup - August 2025September 9, 2025 | thepharmaletter.comTNuveen LLC Invests $286,000 in XOMA Royalty Corporation $XOMASeptember 8, 2025 | marketbeat.comXOMA Royalty Corporation $XOMA Shares Sold by BVF Inc. ILSeptember 5, 2025 | marketbeat.comWall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should KnowSeptember 3, 2025 | zacks.comXOMA Royalty Corporation Executives to Present Company Update at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | quiverquant.comQXOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | globenewswire.comHere's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock NowSeptember 1, 2025 | zacks.comQ3 EPS Estimates for XOMA Royalty Lifted by HC WainwrightAugust 26, 2025 | marketbeat.comHC Wainwright Predicts Stronger Earnings for XOMA RoyaltyAugust 24, 2025 | marketbeat.comXoma’s Strategic Acquisitions and Innovative Financial Strategies Drive Buy RatingAugust 22, 2025 | tipranks.comMural Oncology and XOMA Royalty Corporation Announce Definitive Agreement for Acquisition of Mural OncologyAugust 20, 2025 | quiverquant.comQMural Oncology to be acquired by XOMA unit for up to $2.24/share in cashAugust 20, 2025 | seekingalpha.comMural Oncology Enters Definitive Agreement for Acquisition by XOMA Royalty Corporation in Cash Deal Valued at Approximately $36.2 MillionAugust 20, 2025 | quiverquant.comQMural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per ShareAugust 20, 2025 | globenewswire.comQ3 EPS Estimates for XOMA Royalty Reduced by Leerink PartnrsAugust 19, 2025 | marketbeat.comHow Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15%August 18, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTGX, APTX, FPRX, XOMA, and GLYC Company DescriptionsAptinyx NASDAQ:APTXAptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.Five Prime Therapeutics NASDAQ:FPRXFive Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.GlycoMimetics NASDAQ:GLYCGlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.Protagonist Therapeutics NASDAQ:PTGX$62.14 +2.92 (+4.93%) Closing price 04:00 PM EasternExtended Trading$62.16 +0.02 (+0.02%) As of 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.XOMA Royalty NASDAQ:XOMA$37.59 +0.85 (+2.31%) Closing price 04:00 PM EasternExtended Trading$37.56 -0.04 (-0.09%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
